Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A PHASE 2A, RANDOMIZED, DOUBLE-BLIND, ACTIVE AND PLACEBO-CONTROLLED STUDY OF PF-04171327 IN THE TREATMENT OF THE SIGNS AND SYMPTOMS OF RHEUMATOID ARTHRITIS

NCT00938587 is registered in ClinicalTrials.gov with Pfizer as lead sponsor.

NCT NCT00938587
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00938587 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A PHASE 2A, RANDOMIZED, DOUBLE-BLIND, ACTIVE AND PLACEBO-CONTROLLED STUDY OF PF-04171327 IN THE TREATMENT OF THE SIGNS AND SYMPTOMS OF RHEUMATOID ARTHRITIS
Lead sponsor
Pfizer
Phase
Phase 2
Overall status
Completed
Start date
October 7, 2009
Completion date
July 29, 2010
Enrollment
86 (actual)
Sites
41

Conditions

As the registry lists them; a condition with its own page is linked.

rheumatoid arthritis